Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-11-21 Capital/Financing Update
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
MSB and Oaktree Conclude Refinancing of Senior Debt Facility 2 pages 141.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the refinancing and expansion of a senior debt facility by Mesoblast Limited with Oaktree Capital Management. It details the terms of the new debt facility, including amounts, interest rates, repayment schedule, and warrants issued. The content focuses on financing activities and capital structure changes rather than financial results, management changes, or regulatory filings. There is no indication that this is a full financial report, earnings release, or regulatory filing. The document is not a report publication announcement since it contains substantive information about the financing transaction itself. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-11-21 English
6-K
Regulatory Filings
2021-11-16 English
AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes 3 pages 213.9KB
Investor Presentation Classification · 95% confidence The document is a detailed announcement of clinical trial results presented at the American Heart Association Annual Meeting. It includes extensive data on the Phase 3 trial of rexlemestrocel-L in chronic heart failure, with statistical outcomes and scientific context. The document is not a financial report, regulatory filing, or management discussion. It is a presentation of scientific and clinical trial results at a major conference, which aligns with the definition of an Investor Presentation (IP) as it focuses on detailed results, strategy, and scientific data relevant to investors and stakeholders. The length and detail confirm it is not a brief announcement or a simple press release but a comprehensive presentation of trial findings.
2021-11-14 English
6-K
Regulatory Filings
2021-11-09 English
6-K
Regulatory Filings
2021-11-04 English
Appendix 4C Quarterly Activity Report 10 pages 356.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C QUARTERLY ACTIVITY REPORT' and provides detailed financial and operational highlights for the quarter ended September 30, 2021. It includes comprehensive cash flow statements, revenue details, operating activities, investing and financing activities, and other financial metrics for the quarter. The presence of actual financial data, including cash flow statements and operational highlights, indicates this is a substantive quarterly financial report rather than a brief announcement or a certification. The document also references the ASX Listing Rule 4.7B, which pertains to quarterly reports. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-10-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.